Table 2 Prior and ongoing clinical trials of iron-chelating agents for AKI prevention
From: Iron as an emerging therapeutic target in critically ill patients
Clinical setting | Iron chelation | Primary outcome | Results | NCT number | Year |
|---|---|---|---|---|---|
CKD patients undergoing coronary angiography | Deferiprone: one immediate-release and two extended-release tablets (900 mg) 1–3 h prior to angiography, then every 12 h for 8 days | Biomarker evidence of AKI | Not published | NCT01146925 (completed) | 2011 [116] |
Critical ill patients who develop hypotension, (n = 30) | NAC bolus dose of 50 mg/kg/4 h, followed by 100 mg/kg/day for 2 days and DFO single dose (1 g) administered at 15 mg/kg/h | Serum levels of markers of oxidative damage and inflammatory response | NAC plus DFO administration decreased plasma markers of oxidative damage and creatinine level at hospital discharge | NCT00870883 (completed) | 2012 [117] |
Critical ill patients who develop hypotension, (n = 80) |  | Incidence of AKI | NAC plus DFO did not decrease the incidence of AKI but decreased the severity and duration of AKI | NCT00870883 (completed) | 2016 [118] |
Patients undergoing cardiac surgery | DFO 30Â mg/kg by i.v. infusion over 12Â h | AKI incidence | Not available | NCT04633889 (ongoing) | 2022 [114] |